Submit your requirements and our technical
team will help.
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Zocilurtatug pelitecan | ZL-1310; YL-212 | Phase 3 Clinical | Zai Lab (Shanghai) Co Ltd | Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| Obrixtamig | BI-764532; OBT620 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Glioma; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma | 詳細 |
| Alveltamig | ZG-006; ZG006 | Phase 3 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Carcinoma, Neuroendocrine; Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | 詳細 |
| Gocatamig | HPN-328; MK-6070; DS-3280 | Phase 2 Clinical | Harpoon Therapeutics | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | 詳細 |
| EB-DART-NK01 | EB-DART-NK01 | Phase 2 Clinical | Beijing Biotech | Small Cell Lung Carcinoma | 詳細 |
| 4sCAR-DLL3 CAR-T Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Glioblastoma; Melanoma | 詳細 | |
| SHR-7787 | SHR-7787; SHR7787 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| SHR-4849 | SHR-4849; SHR4849; IDE849; IDE-849 | Phase 2 Clinical | Jiangsu Hengrui Pharmaceutical Group Co Ltd | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 2 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | 詳細 |
| Peluntamig | PT-217 | Phase 2 Clinical | Phanes Therapeutics Inc | Carcinoma, Neuroendocrine; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| ML-261 | ML261; ML-261 | Phase 1 Clinical | Moonlight Bio Inc | Carcinoma, Neuroendocrine; Gastroenteropancreatic neuroendocrine tumor; Prostatic Neoplasms; Small Cell Lung Carcinoma | 詳細 |
| NEUK203-13 | NEUK203-13 | Phase 1 Clinical | Neukio Biotherapeutics (Shanghai) Co Ltd | Neuroendocrine Tumors; Small Cell Lung Carcinoma | 詳細 |
| 111In-ABD147 | Phase 1 Clinical | Abdera Therapeutics Inc | Neuroendocrine Tumors; Prostatic Neoplasms, Castration-Resistant; Solid tumours | 詳細 | |
| 111In-ETN029 | 111In-ETN029 | Phase 1 Clinical | Novartis Pharma Ag | Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma | 詳細 |
| 225Ac-ETN029 | 225Ac-ETN029; [225Ac]Ac-ETN029 | Phase 1 Clinical | Novartis Pharma Ag | Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma | 詳細 |
| HLX-3901 | HLX-3901 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| 177Lu-DTPA-SC16.56 | 177Lu-DTPA-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Carcinoma, Neuroendocrine; Lung Neoplasms; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms | 詳細 |
| SYS-6040 | SYS6040; SYS-6040 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| IBI-3009 | IBI3009; IBI-3009 | Phase 1 Clinical | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | 詳細 | |
| BL-M14D1 | BL-M14D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | 詳細 |
| FZ-AD005 | FZ-AD005; FZAD005; F0041 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Carcinoma, Neuroendocrine; Glioblastoma; Glioma; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh, C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | 詳細 | |
| ABD-147 | ABD-147; 225Ac-ABD147 | Phase 1 Clinical | Abdera Therapeutics Inc | Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| SNC-115 | SNC115; SNC-115 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| RG-6524 | RO-7616789; ALPS-12; RG6524 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | 詳細 |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | 詳細 |
| QLS-31904 | QLS-31904; QLS31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Neuroendocrine Tumors; Small Cell Lung Carcinoma | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab | AMG-757 | Approved | Amgen Inc | Imdelltra | United States | Small Cell Lung Carcinoma | Amgen Inc | 2024-05-16 | Astrocytoma; Brain metastases; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Ganglioglioma; Glioblastoma; Medullary thyroid cancer (MTC); Melanoma; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Paranasal Sinus Diseases; Prostatic Neoplasms; Small Cell Lung Carcinoma; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 |


